Clal Biotechnology Industries News and Activities

Clal Biotechnology Industries is owned by AAR Consortium. AAR Consortium has a direct presence in 13 countries.

AAR Consortium has 49 subsidiaries including Access Industries, ADA Worldwide and Alfa Bank.

They are in:

• Music34%
• Media16%
• Other50%

View the org chart displaying its 6 main executives

Most searched biographies at Clal Biotechnology Industries

• Avi Fischer, Chairman of the Board and Chief Executive Officer
• Gabi Barabash, Director
• Bazil Gamzu, Director

Create your alert
to follow the executive moves at Clal Biotechnology Industries.

AAR Consortium has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 9 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Clal Biotechnology Industries

• אסיפת בעלי מניות 31.10.2024 14:00 – CBI
• MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma | MediWound
• MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers | MediWound
• Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 – Investors – Gamida Cell Ltd.
• BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization | BioLineRx
• BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients With Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer | BioLineRx
• BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition | BioLineRx
• Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
• View more press releases Close

Social media about Clal Biotechnology Industries

• Clal Biotechnology Industries on Wikipedia, Google News & Yahoo Finance
• Clal Biotechnology Industries on LinkedIn, X (Twitter) & YouTube